Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has a diagnosis of schizophrenia~* Requires acute treatment for symptoms of schizophrenia~* Willing and able to be confined to an inpatient study unit for up to 3-4 weeks~* Has experienced at least one previous hospitalization for schizophrenia~* Has been able to achieve outpatient status for more than 3 months in the past year~* Has a body mass index (BMI) between 18.0 and 40.0 kg/m\^2~* Resides in a stable living situation when not hospitalized~* Has an identified reliable caregiver (for example, family member)~* Additional criteria may apply~Exclusion Criteria:~* Poses a current suicide risk~* Pregnant, planning to become pregnant, or breastfeeding~* Initiated first antipsychotic treatment within the past 12 months~* Has received a long-acting injectable antipsychotic in the past 3 months~* Has participated in a clinical study involving any investigational product within the past 3 months, or is currently participating in a clinical study involving an investigational product.~* A positive urine drug test for drugs of abuse~* Additional criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1 (Type: EXPERIMENTAL): Regular injections
- Treatment Group 2 (Type: ACTIVE_COMPARATOR): Regular injections

Based on this trial design, predict the completion outcome and termination type (if applicable).